Global Ursodeoxycholic Acid Drug Market Size By Type (1 Capsule, 2 Tablet), By Application (1 Gallstone, 2 Hepatopathy), By Region, And Segment Forecasts, 2023 to 2032

The Global Ursodeoxycholic Acid (UDCA) Drug Market was valued at USD 740 million in 2023 and is anticipated to reach USD 1.21 billion by 2031, expanding at a CAGR of 6.6% during the forecast period from 2023 to 2031. Ursodeoxycholic acid, a bile acid, is primarily used to treat primary biliary cholangitis (PBC), gallstones, and certain liver disorders. The increasing prevalence of liver-related diseases, rising geriatric population, and growing healthcare awareness are key factors contributing to the market's expansion.

UDCA drugs are gaining widespread clinical acceptance due to their proven efficacy and favorable safety profile. Furthermore, pharmaceutical innovations, such as advanced formulations and combination therapies, are bolstering demand across both developed and developing healthcare markets.

Drivers

1. Rising Prevalence of Liver and Gallbladder Disorders:

The increasing incidence of chronic liver diseases, including cholestatic liver disorders and gallstones, particularly among aging populations, is significantly boosting demand for UDCA-based therapies.

2. Favorable Drug Safety and Efficacy Profile:

UDCA is recognized for its minimal side effects and long-term tolerability. Its use in reducing liver enzyme levels and improving bile flow makes it a preferred choice in hepatology.

3. Growth in Geriatric Population:

As age-related liver conditions become more common, especially in developed economies, the need for effective and well-tolerated hepatoprotective drugs like UDCA is rising.

Restraints

1. Availability of Alternative Therapies:

The development of newer, targeted therapies for liver diseases, such as obeticholic acid, may limit the market potential of UDCA in specific treatment scenarios.

2. Stringent Regulatory Approvals:

The pharmaceutical industry is tightly regulated, and any delay in approvals or compliance hurdles can slow down the commercialization of new UDCA formulations or generic versions.

Opportunity

1. Market Expansion in Emerging Economies:

Rising healthcare infrastructure investments and growing awareness of liver health in emerging markets like India, Brazil, and Southeast Asia create strong growth opportunities for UDCA drug manufacturers.

2. Research into Novel Indications:

Ongoing clinical research exploring UDCA’s efficacy in treating cystic fibrosis-related liver disease, non-alcoholic steatohepatitis (NASH), and other hepatobiliary disorders could unlock additional market segments.

Market by System Type Insights

The Tablets and Capsules segment dominated the global UDCA market in 2023, accounting for the majority share due to its ease of administration and patient adherence. However, the Suspension formulation is gaining traction, especially in pediatric and geriatric populations, and is projected to witness significant growth.

Market by End-use Insights

Hospital Pharmacies held the largest share in 2023, driven by the increasing diagnosis of liver disorders in clinical settings. The Retail Pharmacies segment is expected to grow rapidly owing to greater accessibility and the rise of over-the-counter (OTC) hepatoprotective drugs in several countries.

Market by Regional Insights

North America dominated the UDCA drug market in 2023, owing to a high prevalence of liver diseases, strong pharmaceutical distribution networks, and favorable insurance coverage. Asia-Pacific is forecast to experience the fastest growth, supported by rising healthcare expenditure, an expanding middle class, and growing disease awareness in countries such as China, India, and Japan.

Competitive Scenario

Prominent players in the Global Ursodeoxycholic Acid Drug Market include:

Dr. Reddy’s Laboratories Ltd.

Zydus Lifesciences Ltd.

Daewoong Pharmaceutical Co., Ltd.

Apotex Inc.

Dipharma Francis S.r.l.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Sanofi S.A.

These companies are actively engaged in regulatory approvals, expanding their geographic presence, and investing in R&D for novel UDCA applications.

Scope of Work – Global Ursodeoxycholic Acid Drug Market

Key Market Developments

2023: Dr. Reddy’s launched a generic UDCA formulation in the U.S. for treatment of PBC and cholesterol gallstones.

2024: Daewoong Pharmaceutical expanded its UDCA drug portfolio to the Middle East through strategic partnerships.

2025: Zydus Lifesciences began Phase II trials to evaluate UDCA’s efficacy in non-alcoholic fatty liver disease (NAFLD).

FAQs

1) What is the current market size of the Global Ursodeoxycholic Acid Drug Market?

The market was valued at USD 740 million in 2023.

2) What is the major growth driver of the Global Ursodeoxycholic Acid Drug Market?

The increasing prevalence of liver and gallbladder disorders and the aging global population.

3) Which is the largest region during the forecast period in the Global Ursodeoxycholic Acid Drug Market?

North America accounted for the largest share in 2023, while Asia-Pacific is projected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Ursodeoxycholic Acid Drug Market?

The Tablets and Capsules segment led the market in 2023.

5) Who are the key market players in the Global Ursodeoxycholic Acid Drug Market?

Dr. Reddy’s, Zydus Lifesciences, Daewoong, Sun Pharma, Teva, and Apotex are among the leading players.